Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).
Breast Cancer Res Treat
; 201(3): 409-415, 2023 Oct.
Article
in En
| MEDLINE
| ID: mdl-37480384
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Quality of Life
/
Breast Neoplasms
Type of study:
Observational_studies
Aspects:
Patient_preference
Limits:
Female
/
Humans
Language:
En
Journal:
Breast Cancer Res Treat
Year:
2023
Document type:
Article
Affiliation country:
Japan